Novo Nordisk/$NVO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Employees
78,554
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk Metrics
BasicAdvanced
$209B
13.24
$3.60
0.35
$1.23
1.73%
Price and volume
Market cap
$209B
Beta
0.35
52-week high
$110.30
52-week low
$45.05
Average daily volume
16M
Dividend rate
$1.23
Financial strength
Current ratio
0.776
Quick ratio
0.533
Long term debt to equity
52.491
Total debt to equity
59.574
Dividend payout ratio (TTM)
49.88%
Interest coverage (TTM)
19.21%
Profitability
EBITDA (TTM)
25,510.746
Gross margin (TTM)
83.44%
Net profit margin (TTM)
32.88%
Operating margin (TTM)
48.69%
Effective tax rate (TTM)
21.33%
Revenue per employee (TTM)
$619,680
Management effectiveness
Return on assets (TTM)
21.11%
Return on equity (TTM)
71.46%
Valuation
Price to earnings (TTM)
13.242
Price to revenue (TTM)
4.352
Price to book
7.97
Price to tangible book (TTM)
21.38
Price to free cash flow (TTM)
22.534
Free cash flow yield (TTM)
4.44%
Free cash flow per share (TTM)
2.114
Dividend yield (TTM)
2.58%
Forward dividend yield
1.73%
Growth
Revenue change (TTM)
16.64%
Earnings per share change (TTM)
10.06%
3-year revenue growth (CAGR)
23.59%
10-year revenue growth (CAGR)
11.78%
3-year earnings per share growth (CAGR)
26.29%
10-year earnings per share growth (CAGR)
13.82%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:
WSJ2 days ago
Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
Reuters2 days ago
Denmark compensates patients for vision loss linked to Novo Nordisk drugs
Reuters2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $209B as of November 23, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 13.24 as of November 23, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of November 23, 2025, the dividend rate is $1.23062 and the yield is 1.73%. Novo Nordisk has a payout ratio of 49.88% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.